MiNK Therapeutics to Present New Data on iNKT Cell Therapy at ASGCT 2026

Presentation to highlight context-dependent activity of investigational agenT-797 in cancer and severe respiratory disease

Apr. 2, 2026 at 11:50am

Got story updates? Submit your updates here. ›

MiNK Therapeutics, a clinical-stage biopharmaceutical company, announced that an abstract featuring its investigational iNKT cell therapy, agenT-797, has been accepted for presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in May 2026. The presentation will focus on the adaptive immune modulation capabilities of agenT-797 in cancer and acute respiratory distress syndrome (ARDS).

Why it matters

iNKT cell therapies like agenT-797 represent a promising new approach to treating hard-to-treat cancers and severe inflammatory conditions by harnessing the dual power of innate and adaptive immunity. The presentation of new data at a major scientific conference like ASGCT could help advance the development of this innovative therapy and provide hope for patients with limited treatment options.

The details

The abstract, titled "AgenT-797 Allogeneic iNKT Cell Therapy Demonstrates Adaptive Immune Modulation in Cancer and ARDS", will be presented by Terese C. Hammond, MD, the Program Director of Pulmonary and Critical Care at Kaweah Health Medical Center and the Head of Inflammatory and Pulmonary Diseases at MiNK Therapeutics. The presentation will highlight the context-dependent activity of agenT-797, MiNK's investigational off-the-shelf iNKT cell therapy, in boosting peripheral memory T-cell activation, enhancing tumor infiltration, and potentially improving outcomes for patients with solid cancers and severe respiratory pathology.

  • The ASGCT Annual Meeting will take place from May 11-15, 2026, in Boston, MA.
  • MiNK Therapeutics announced the acceptance of the abstract on April 2, 2026.

The players

MiNK Therapeutics, Inc.

A clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer.

Terese C. Hammond, MD

The Program Director of Pulmonary and Critical Care at Kaweah Health Medical Center and the Head of Inflammatory and Pulmonary Diseases at MiNK Therapeutics.

agenT-797

MiNK Therapeutics' investigational allogeneic invariant natural killer T (iNKT) cell therapy currently in clinical development for GVHD, solid tumors, and severe pulmonary inflammation.

Got photos? Submit your photos here. ›

What they’re saying

“AgenT-797 Allogeneic iNKT Cell Therapy Demonstrates Adaptive Immune Modulation in Cancer and ARDS”

— Terese C. Hammond, MD, Program Director of Pulmonary and Critical Care, Kaweah Health Medical Center; Head of Inflammatory and Pulmonary Diseases, MiNK Therapeutics

What’s next

Additional information on the poster presentation, including session location and timing details, will be made available by ASGCT via the ASGCT Annual Meeting conference program website in mid-April.

The takeaway

The presentation of new data on MiNK Therapeutics' investigational iNKT cell therapy, agenT-797, at the prestigious ASGCT Annual Meeting highlights the potential of this innovative approach to address hard-to-treat cancers and severe inflammatory conditions by harnessing the dual power of innate and adaptive immunity.